Summit Therapeutics Inc. Quarterly Debt-to-equity in % from Q1 2021 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Summit Therapeutics Inc. quarterly Debt-to-equity history and growth rate from Q1 2021 to Q2 2024.
Summit Therapeutics Inc. Debt-to-equity for the quarter ending June 30, 2024 was 126 %, a 19.2% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	126	-29.9	-19.2%	Jun 30, 2024
Q1 2024	145	-18	-11%	Mar 31, 2024
Q4 2023	112	-62.3	-35.6%	Dec 31, 2023
Q3 2023	187	+142	+318%	Sep 30, 2023
Q2 2023	156	+105	+207%	Jun 30, 2023
Q1 2023	163	+127	+348%	Mar 31, 2023
Q4 2022	175	+132	+306%	Dec 31, 2022
Q3 2022	44.7	+3.19	+7.68%	Sep 30, 2022
Q2 2022	50.8	+2.54	+5.27%	Jun 30, 2022
Q1 2022	36.4	-22.2	-37.9%	Mar 31, 2022
Q4 2021	43			Dec 31, 2021
Q3 2021	41.6			Sep 30, 2021
Q2 2021	48.2			Jun 30, 2021
Q1 2021	58.7			Mar 31, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.